Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -5.60 is 99% above its 5-year average of -468.76, near the high end of its 5-year range (-1269.25–-5.60).
89.54% above its 12-month average of -53.55.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.19.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-5.60
EARNINGS PER SHARE (EPS) AVG TTM
-53.55
EARNINGS PER SHARE (EPS) AVG 3Y
-292.57
EARNINGS PER SHARE (EPS) AVG 5Y
-468.76
EARNINGS PER SHARE (EPS) AVG 10Y
-1079.91
EARNINGS PER SHARE (EPS) AVG 15Y
-417.84
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+89.54%
CURRENT VS 3Y AVG
+98.09%
CURRENT VS 5Y AVG
+98.81%
CURRENT VS 10Y AVG
+99.48%
CURRENT VS 15Y AVG
+98.66%
CURRENT VS 20Y AVG
N/A
Processa Pharmaceuticals, Inc.
Market Cap
$4.20M
Earnings Per Share (EPS)
-5.60
TTM Avg
-53.55
3Y Avg
-292.57
5Y Avg
-468.76
Market Cap
$4.23M
Earnings Per Share (EPS)
-0.76
TTM Avg
-0.88
3Y Avg
-0.66
5Y Avg
-0.44
Market Cap
$4.12M
Earnings Per Share (EPS)
-6.05
TTM Avg
-42.97
3Y Avg
-23.50
5Y Avg
-16.51
Market Cap
$4.09M
Earnings Per Share (EPS)
N/A
TTM Avg
-60.73
3Y Avg
-46926.80
5Y Avg
-32538.00
Market Cap
$4.34M
Earnings Per Share (EPS)
-9.39
TTM Avg
-11.95
3Y Avg
-11.32
5Y Avg
-8.88
Market Cap
$4.02M
Earnings Per Share (EPS)
-211.18
TTM Avg
-432751.00
3Y Avg
-875189.50
5Y Avg
-22462429.83
Market Cap
$4.51M
Earnings Per Share (EPS)
-4.39
TTM Avg
-44.24
3Y Avg
-644.57
5Y Avg
-610.60
Market Cap
$3.79M
Earnings Per Share (EPS)
-0.91
TTM Avg
-1.99
3Y Avg
-3.92
5Y Avg
-2.83
Market Cap
$4.66M
Earnings Per Share (EPS)
-6.95
TTM Avg
-22.18
3Y Avg
-69.66
5Y Avg
-91.58
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | $4.20M | -5.60 | -53.55 | -292.57 | -468.76 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | -0.76 | -0.88 | -0.66 | -0.44 |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.12M | -6.05 | -42.97 | -23.50 | -16.51 |
| GRI Bio, Inc. (GRI)vs › | $4.09M | N/A | -60.73 | -46926.80 | -32538.00 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -9.39 | -11.95 | -11.32 | -8.88 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.02M | -211.18 | -432751.00 | -875189.50 | -22462429.83 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | -4.39 | -44.24 | -644.57 | -610.60 |
| Evogene Ltd. (EVGN)vs › | $3.79M | -0.91 | -1.99 | -3.92 | -2.83 |
| CalciMedica, Inc. (CALC)vs › | $4.66M | -6.95 | -22.18 | -69.66 | -91.58 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.71M | -2.41 | 0.21 | -0.40 | -0.72 |
Trailing EPS (TTM)
$-5.60
Forward EPS (Est.)
$-6.00
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -10.36 |
| 2024-12-31 | -96.75 |
| 2023-12-31 | -212.00 |
| 2022-12-31 | -851.19 |
| 2021-12-31 | -373.00 |
| 2020-12-31 | -1269.25 |
| 2019-12-31 | -304.25 |
| 2018-12-31 | -355.00 |
| 2017-12-31 | -200.00 |
| 2016-12-31 | -747.25 |
| 2015-12-31 | -7460.00 |
| 2014-12-31 | -16660.00 |
| 2013-12-31 | -14945.00 |
| 2012-12-31 | -16917.25 |
| 2011-12-31 | -510.00 |
| 2010-12-31 | -85.00 |
